1.Alteration and significance of serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma: a retrospective study based on LEGEND-2.
Xue Zhu XU ; Rui LIU ; Wan Hong ZHAO ; Yun YANG ; Jie LIU ; Yu Gang ZHANG ; Ju BAI ; Ai Li HE
Chinese Journal of Hematology 2023;44(10):838-844
Objective:b> To explore the dynamic changes in serum lipid levels and nutritional status during BCMA-CAR-T-cell therapy in patients with refractory or relapsed multiple myeloma (R/R MM) based on LEGEND-2. Methods:b> The data of patients with R/R MM who underwent BCMA-CAR-T therapy at our hospital between March 30, 2016, and February 6, 2018, were retrospectively collected. Serum lipid levels, controlled nutritional status (CONUT) score, and other clinical indicators at different time points before and after CAR-T-cell infusion were compared and analyzed. The best cut-off value was determined by using the receiver operator characteristic (ROC) curve. The patients were divided into high-CONUT score (>6.5 points, malnutrition group) and low-CONUT score groups (≤6.5 points, good nutrition group), comparing the progression-free survival (PFS) and total survival (OS) of the two groups using Kaplan-Meier survival analysis. Results:b> Before the infusion of CAR-T-cells, excluding triglycerides (TG), patients' serum lipid levels were lower than normal on average. At 8-14 d after CAR-T-cell infusion, serum albumin (ALB), total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and apolipoprotein A1 (Apo A1) levels dropped to the minimum, whereas CONUT scores reached the maximum. In addition to TG, apolipoprotein B (Apo B) levels increased compared with baseline. After CAR-T-cell therapy, the patients' serum lipid levels significantly increased with well-improved nutritional status. Spearman's related analysis showed that TC, HDL, and ApoA1 levels after CAR-T-cell injection were significantly negatively correlated with the grade of cytokine-release syndrome (CRS) (r=-0.548, P=0.003; r=-0.444, P=0.020; r=-0.589, P=0.001). Furthermore, survival analysis indicated that the CONUT score was unrelated to PFS, and the median OS of patients with R/R MM in the high-CONUT score group was shorter than that in the low-CONUT score group (P=0.046) . Conclusions:b> During CAR-T-cell therapy, hypolipidemia and poor nutritional status were aggravated, which is possibly related to CRS. The patients' serum lipid levels and nutritional status were significantly improved after CAR-T-cell treatment. The CONUT score affected the median OS in patients treated with CAR-T-cells. Therefore, specific screening and intervention for nutritional status in patients receiving CAR-T-cell therapy are required.
Humans
;
Multiple Myeloma/drug therapy*
;
Nutritional Status
;
Retrospective Studies
;
Receptors, Chimeric Antigen/therapeutic use*
;
B-Cell Maturation Antigen/therapeutic use*
;
Cell- and Tissue-Based Therapy
;
Lipids/therapeutic use*
2.Observation of liver indexes in patients with relapsed/refractory multiple myeloma treated with CAR-T-cells based on BCMA.
Qian SUN ; Yue Kun QI ; Kun Ming QI ; Zhi Ling YAN ; Hai CHENG ; Wei CHEN ; Feng ZHU ; Wei SANG ; De Peng LI ; Jiang CAO ; Ming SHI ; Zhen Yu LI ; Kai Lin XU
Chinese Journal of Hematology 2023;44(10):832-837
Objective:b> To observe the characteristics of the evolution of liver indexes in patients with relapsed/refractory multiple myeloma (RRMM) treated with CAR-T-cells based on BCMA. Methods:b> Retrospective analysis was performed of patients with RRMM who received an infusion of anti-BCMA CAR-T-cells and anti-BCMA combined with anti-CD19 CAR-T-cells at our center between June 1, 2019, and February 28, 2023. Clinical data were collected to observe the characteristics of changes in liver indexes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL) in patients, and its relationship with cytokine-release syndrome (CRS) . Results:b> Ninety-two patients were included in the analysis, including 41 patients (44.6%) in the group receiving a single infusion of anti-BCMA CAR-T-cells, and 51 patients (55.4%) in the group receiving an infusion of anti-BCMA combined with anti-CD19 CAR-T-cells. After infusing CAR-T-cells, 31 patients (33.7%) experienced changes in liver indexes at or above grade 2, which included 20 patients (21.7%) with changes in one index, five patients (5.4%) with changes in two indexes, and six patients (6.5%) with changes in three or more indexes. The median time of peak values of ALT and AST were d17 and d14, respectively, and the median duration of exceeding grade 2 was 5.0 and 3.5 days, respectively. The median time of peak values of TBIL and DBIL was on d19 and d21, respectively, and the median duration of exceeding grade 2 was 4.0 days, respectively. The median time of onset of CRS was d8, and the peak time of fever was d9. The ALT, AST, and TBIL of patients with CRS were higher than those of patients without CRS (P=0.011, 0.002, and 0.015, respectively). CRS is an independent factor that affects ALT and TBIL levels (OR=19.668, 95% CI 18.959-20.173, P=0.001). The evolution of liver indexes can be reversed through anti-CRS and liver-protection treatments, and no patient died of liver injury. Conclusions:b> In BCMA-based CAR-T-cell therapy for RRMM, CRS is an important factor causing the evolution of liver indexes. The evolution of liver indexes after CAR-T-cell infusion is transient and reversible after treatment.
Humans
;
Antigens, CD19
;
B-Cell Maturation Antigen/therapeutic use*
;
Bilirubin
;
Immunotherapy, Adoptive
;
Liver
;
Multiple Myeloma/drug therapy*
;
Retrospective Studies
;
T-Lymphocytes
3.Progress in the study of BLyS and APRIL on regulating T cell responses in rheumatoid arthritis.
Acta Pharmaceutica Sinica 2013;48(7):979-985
B lymphocyte stimulator (BLyS), a tumor neurosis factor ligand superfamily, is an important factor of B cell survival and activation. However, BLyS also regulates T cell activation and survival, playing key roles in T cell-mediated autoimmune disorders. In the paper, we introduced the mechanisms of BLyS and a proliferation-inducing ligand (APRIL) regulating T cell responses and their roles in rheumatoid arthritis (RA).
Animals
;
Antibodies, Monoclonal, Humanized
;
therapeutic use
;
Arthritis, Rheumatoid
;
drug therapy
;
metabolism
;
pathology
;
B-Cell Activating Factor
;
metabolism
;
B-Cell Activation Factor Receptor
;
metabolism
;
B-Cell Maturation Antigen
;
metabolism
;
B-Lymphocytes
;
metabolism
;
pathology
;
Humans
;
Lymphocyte Activation
;
Recombinant Fusion Proteins
;
therapeutic use
;
T-Lymphocytes
;
metabolism
;
pathology
;
Transmembrane Activator and CAML Interactor Protein
;
metabolism
;
Tumor Necrosis Factor Ligand Superfamily Member 13
;
metabolism